Calendar of Events.

Event Description:

Biotech: The New Normal?

As the global economy shows signs of recovery, how is the global biotechnology industry faring?

Please join the Chamber and Ernst & Young to hear the findings of Ernst & Young's 24th annual biotech industry report. This report will, as always, summarize the sector’s performance using key metrics – financial performance, financing, deals and pipeline productivity.

However, the aggregate numbers don’t tell the entire story and new questions emerge:

• How have new economic realities affected companies of different sizes and levels of maturity?
• At a time when companies, households and governments everywhere are having to do more with less, what approaches are biotech firms adopting to efficiently and effectively develop drugs and other products?
• How are companies raising funds, using capital more efficiently and boosting the productivity of R&D?
• Are investors adopting new models to make the numbers work?

Join us as we host a panel discussion to explore the world of biotech in the time of the "new normal."

Welcome and Overview of  Beyond Borders 2010 - E&Y's Global Biotechnology Report
Glen Giovannetti, Global Biotechnology Leader, Ernst & Young LLP

Panel:
Moderator: Christian Plaza, Partner-in-Charge, Boston Office, Cooley LLP
Panelists:
Richard Douglas, PhD, Senior Vice President of Corporate Development,Genzyme Corp.
Derek Lee, Chief Financial and Corporate Development Office, Talaris Advisors LLC
Michael Clayman, CEO, Flexion Therapeutics
Mark Levin, Managing Partner/Co-Founder, Third Rock Ventures